Notes: the brand name of a drug appears in parentheses in the first column. All attribute information is based on the experiences of patients in Phase clinical 3 trials. The median survival is measured in months. Cetuximab was approved without demonstrating a longer survival, and therefore survival is coded as not available (N/A). Response rate is the percentage of patients whose tumor shrunk. Time to progression is the mean number of months for a tumor to advance to a more severe stage. Second-line therapies are approved by the FDA to be used on patients who have been treated previously with a different therapy. The final six columns measure the percentage of patients who experienced a grade 3 or grade 4 (on a 1-4 scale, where 4 is the most severe) side effect of a particular type.